BENEFIT OF ABIRATERONE ACETATE PLUS PREDNISONE (AA plus P) ADDED TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH HIGH-RISK, NEWLY DIAGNOSED METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

被引：0
|
作者：
Metin, H. [1 ]
McQuarrie, K. [2 ]
Thilakarathne, M. [3 ]
Diels, J. [3 ]
Ito, T. [4 ]
Li, T. [5 ]
Sulur, G. [6 ]
Chi, K. N. [7 ]
Fizazi, K. [8 ]
机构：
[1] Janssen Cilag GmbH, North Rhine Westphalia, Germany
[2] Janssen Res & Dev, Spring House, PA USA
[3] Janssen Cilag, Beerse, Belgium
[4] Janssen Cilag, High Wycombe, Bucks, England
[5] Janssen Global Serv, Raritan, NJ USA
[6] Janssen Res & Dev, Los Angeles, CA USA
[7] BC Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada
[8] Univ Paris Sud, Gustave Roussy, Villejuif, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.317
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN171
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [11] Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
    Park, Dong Jin
    Kwon, Tae Gyun
    Park, Jae Young
    Joung, Jae Young
    Ha, Hong Koo
    Jeon, Seong Soo
    Hong, Sung-Hoo
    Park, Sungchan
    Lee, Seung Hwan
    Cho, Jin Seon
    Park, Sung-Woo
    Kwon, Se Yun
    Jo, Jung Ki
    Park, Hong Seok
    Lee, Sang-Cheol
    Kwon, Dong Deuk
    Kim, Sun Il
    Park, Sang Hyun
    Kim, Soodong
    Jeong, Chang Wook
    Kwak, Cheol
    Choi, Seock Hwan
    WORLD JOURNAL OF MENS HEALTH, 2024, 42 (03): : 620 - 629
  • [12] Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer
    Hoyle, A. P.
    Ali, S. A.
    James, N. D.
    Parker, C. C.
    Cook, A. D.
    Attard, G.
    Chowdhury, S.
    Cross, W.
    Dearnaley, D. P.
    de Bono, J. S.
    Gilson, C. E.
    Gillessen, S.
    Jones, R.
    Matheson, D.
    Mason, M. D.
    Ritchie, A.
    Russell, M.
    Parmar, M. K.
    Sydes, M. R.
    Clarke, N. W.
    ANNALS OF ONCOLOGY, 2018, 29 : 722 - 722
  • [13] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
    Fizazi, Karim
    Namphuong Tran
    Enrique Fein, Luis
    Matsubara, Nobuaki
    Rodriguez Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [14] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
    Takashi Ueda
    Kazutoshi Fujita
    Mitsuhisa Nishimoto
    Takumi Shiraishi
    Masatsugu Miyashita
    Naruhiro Kayukawa
    Yuichi Nakamura
    Satoshi Sako
    Ryota Ogura
    Atsuko Fujihara
    Takafumi Minami
    Fumiya Hongo
    Koji Okihara
    Kazuhiro Yoshimura
    Hirotsugu Uemura
    Osamu Ukimura
    World Journal of Urology, 2022, 40 : 2939 - 2946
  • [15] Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients
    Ueda, Takashi
    Fujita, Kazutoshi
    Nishimoto, Mitsuhisa
    Shiraishi, Takumi
    Miyashita, Masatsugu
    Kayukawa, Naruhiro
    Nakamura, Yuichi
    Sako, Satoshi
    Ogura, Ryota
    Fujihara, Atsuko
    Minami, Takafumi
    Hongo, Fumiya
    Okihara, Koji
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    Ukimura, Osamu
    WORLD JOURNAL OF UROLOGY, 2022, 40 (12) : 2939 - 2946
  • [16] A randomized phase II study of ADT plus abiraterone versus ADT plus abiraterone plus docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer
    Fenton, Sarah Elizabeth
    Kocherginsky, Masha
    VanderWeele, David James
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [17] Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
    Hu, Linjun
    Zhao, Qinxin
    Bai, Hongsong
    Xie, Chengming
    Shan, Xingli
    Lu, Dehu
    Chen, Yonghai
    Han, Dongdong
    Xiao, Zejun
    Tian, Jun
    Wang, Dong
    Bi, Xingang
    Xing, Nianzeng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4369 - 4377
  • [18] Sequential ADT and abiraterone acetate plus prednisone versus combined ADT with abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer: A propensity score-matched study.
    Yang, Zhenyu
    Zhao, Diwei
    Wang, Jun
    Long, Xingbo
    Chen, Dong
    Zhou, Fangjian
    Li, Yonghong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [19] Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.
    Aguiar, Pedro Nazareth
    Tan, Pui San
    Simko, Sarah
    Barreto, Carmelia Maria Noia
    Aguiar, Barbara Gutierres
    Del Giglio, Auro
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
    Kwon, Whi-An
    Joung, Jae Young
    Lee, Jung Eun
    Choi, Se Young
    Kim, Sung Han
    Seo, Ho Kyung
    Lee, Kang Hyun
    Kim, Choung-Soo
    INVESTIGATIVE AND CLINICAL UROLOGY, 2019, 60 (03) : 195 - 201
12345